Vector Science & Therapeutics Corp．周二宣布，公司董事会已批准向部分董事授予206，610份股票期权，行权价为每股1.69加元。此举正值公司近期完成多项战略布局、加速推进增长战略之际。

Vector Science & Therapeutics Corp. (TSXV: PAIN) today announced the appointment of Dexter Fowler as Chief Athletic Officer ...

Dr. Alexander Dobranowski, President, Director, and Co-Founder of HEALWELL AI, brings healthcare AI and clinical leadership to the Vector board. Scott Kelly, a proven C-level leader with 22+ years of ...

Option agreement Supports Vector's Entry into the $80.8 Billion Peptide Market with 22 Novel Pharmaceutical-Grade Formulations MEQUON, Wis., May 13, 2026 /PRNewswire/ -- Vector Science & Therapeutics ...

Vector Science & Therapeutics Corp. (TSXV: PAIN) today announced the appointment of Darryl Drake Jr. as President of Valor and Chairman of the Athletic Board of Directors. Valor is a newly formed ...

Option agreement Supports Vector's Entry into the $80.8 Billion Peptide Market with 22 Novel Pharmaceutical-Grade Formulations FDA-Registered, cGMP Manufacturing-- MPP operates a modern 35,000 sq. ft.

MEQUON, Wis., May 1, 2026 /PRNewswire/ --(TSXV: PAIN) — Vector Science & Therapeutics (the "Company") today announced the filing of a provisional patent application covering a novel catheter-based ...

Vancouver, British Columbia--(Newsfile Corp. - April 24, 2026) - Vector Science and Therapeutics Corp. (TSXV: PAIN) (formerly OpenSesame Acquisition Corp.) ("Vector" or the "Company") is pleased to ...